Krishnaiah Yellela S, Al-Saidan Saleh M
Department of Pharmaceutics, Faculty of Pharmacy, Kuwait University, Safat, Kuwait.
Curr Drug Deliv. 2008 Jan;5(1):70-6. doi: 10.2174/156720108783330970.
The objective of the study was to design membrane-controlled transdermal therapeutic system (TTS) for trimetazidine. The optimization of (i) concentration of ethanol-water solvent system, (ii) HPMC concentration of drug reservoir and (iii) limonene concentration in 2% w/v HPMC gel was done based on the in vitro permeation of trimetazidine across excised rat epidermis. A limonene-based membrane-controlled TTS of trimetazidine was fabricated and evaluated for its in vivo drug release in rabbit model. The in vitro permeation of trimetazidine from water, ethanol and selected concentrations (25, 50 and 75% v/v) of ethanol-water co-solvent systems showed that 50% v/v of ethanol-water solvent system provided an optimal transdermal flux of 233.1+/-3.8 microg/cm(2.)h. The flux of the drug decreased to 194.1+/-7.4 microg/cm(2.)h on adding 2% w/v of HPMC to ethanolic (50% v/v ethanol-water) solution of trimetazidine. However, on adding selected concentrations of limonene (0, 2, 4, 6 and 8% w/v) to 2% w/v HPMC gel drug reservoir, the flux of the drug increased to 365.5+/-7.1 microg/cm(2.)h. Based on these results, 2% w/v HPMC gel drug reservoir containing 6% w/v of limonene was chosen as an optimal formulation for studying the influence of rate-controlling EVA2825 membrane and adhesive-coated EVA2825 membrane. The flux of the drug across EVA2825 membrane (mean thickness 31.2 microm) decreased to 285.8+/-2.2 microg/cm(2.)h indicating that the chosen membrane was effective as rate-controlling membrane. On applying an adhesive coat (mean thickness 10.2 microm) to EVA2825 membrane, the drug flux further decreased to 212.4+/-2.6 microg/cm(2.)h. However, the flux of the drug across adhesive-coated EVA2825 membrane-rat epidermis composite was 185.9+/-2.9 microg/cm(2.)h, which is about 2-times higher than the desired flux. The fabricated limonene-based TTS patch of trimetazidine showed a mean steady state plasma concentration of 71.5 ng/mL for about 14 h with minimal fluctuation when tested in rabbits. It was concluded from the investigation that the limonene-based TTS patch of trimetazidine provided constant drug delivery across the skin in rabbit model.
本研究的目的是设计曲美他嗪的膜控型透皮治疗系统(TTS)。基于曲美他嗪透过切除的大鼠表皮的体外渗透情况,对(i)乙醇 - 水溶剂系统的浓度、(ii)药物储库中羟丙基甲基纤维素(HPMC)的浓度以及(iii)2% w/v HPMC凝胶中柠檬烯的浓度进行了优化。制备了基于柠檬烯的曲美他嗪膜控型TTS,并在兔模型中评估了其体内药物释放情况。曲美他嗪在水、乙醇以及选定浓度(25%、50%和75% v/v)的乙醇 - 水共溶剂系统中的体外渗透情况表明,50% v/v的乙醇 - 水溶剂系统提供了233.1±3.8 μg/cm²·h的最佳透皮通量。在曲美他嗪的乙醇溶液(50% v/v乙醇 - 水)中添加2% w/v的HPMC后,药物通量降至194.1±7.4 μg/cm²·h。然而,在2% w/v HPMC凝胶药物储库中添加选定浓度的柠檬烯(0、2、4、6和8% w/v)后,药物通量增加至365.5±7.1 μg/cm²·h。基于这些结果,选择含有6% w/v柠檬烯的2% w/v HPMC凝胶药物储库作为研究控释乙烯 - 醋酸乙烯共聚物(EVA2825)膜和涂有粘合剂的EVA2825膜影响的最佳配方。药物透过EVA2825膜(平均厚度31.2微米)的通量降至285.8±2.2 μg/cm²·h,表明所选膜作为控释膜是有效的。在EVA2825膜上涂覆一层粘合剂(平均厚度10.2微米)后,药物通量进一步降至212.4±2.6 μg/cm²·h。然而,药物透过涂有粘合剂的EVA2825膜 - 大鼠表皮复合物的通量为185.9±2.9 μg/cm²·h,约为所需通量的2倍。制备的基于柠檬烯的曲美他嗪TTS贴片在兔体内测试时,显示出约14小时的平均稳态血浆浓度为71.5 ng/mL,波动极小。从该研究得出结论,基于柠檬烯的曲美他嗪TTS贴片在兔模型中能通过皮肤持续给药。